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A B S T R A C T
Background: A low eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio is known to be associated
with cardiovascular events. However, the relationship between the EPA/AA ratio and coronary plaque
vulnerability assessed by optical coherence tomography (OCT) has not been examined thoroughly. This
study examined the relationship between the EPA/AA ratio and coronary plaque vulnerability assessed
by OCT in patients with acute coronary syndrome (ACS).
Methods: We evaluated 59 ACS patients who had undergone percutaneous coronary intervention using
OCT. We divided them into 2 groups according to OCT ﬁndings—those with and without thin-cap
ﬁbroatheroma (TCFA)—and compared the EPA/AA ratio between the groups.
Results: We identiﬁed 32 and 27 patients with and without TCFA, respectively. The EPA/AA ratio was
signiﬁcantly lower in patients with TCFA than in those without TCFA [0.35, interquartile range (0.21–
0.44) vs. 0.54, interquartile range (0.42–0.70); p < 0.001]. In multivariate logistic regression analysis, the
EPA/AA ratio was an independent predictor of TCFA (odds ratio, 0.09; 95% conﬁdence interval, 0.007–
0.99; p = 0.049). The EPA/AA ratio and ﬁbrous cap thickness showed a signiﬁcant positive correlation
(Spearman r = 0.46; p < 0.001). Furthermore, receiver operating characteristic curve analysis showed
that an EPA/AA ratio < 0.46 could predict TCFA (81.3%, sensitivity; 74.1%, speciﬁcity).
Conclusions: A low serum EPA/AA ratio is signiﬁcantly associated with coronary plaque vulnerability
assessed by OCT in ACS patients.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Eicosapentaenoic acid (EPA) is a member of a group of n-3
polyunsaturated fatty acids (PUFAs) derived from ﬁsh or ﬁsh oil.
Epidemiologic data suggest that long-term intake of n-3 PUFAs
plays an important role in reducing the occurrence of adverse
cardiovascular events [1]. Furthermore, administration of puriﬁed
EPA has been shown to be effective in the prevention of major
coronary events [2]. On the other hand, arachidonic acid (AA) is
classiﬁed under the category of n-6 PUFAs, and a low EPA/AA ratio
is associated with a higher incidence of cardiac events [3,4]. In
addition, the increment of EPA/AA ratio is reported to be associated* Corresponding author at: 1-847 Amanuma, Omiya-ku, Saitama City, Saitama
330-8503, Japan. Tel.: +81 48 647 2111; fax: +81 48 648 5188.
E-mail address: funahiro@omiya.jichi.ac.jp (H. Funayama).
http://dx.doi.org/10.1016/j.jjcc.2015.01.008
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightswith a reduction in the brachial-ankle pulse wave velocity that is a
surrogate marker of atherosclerosis [5].
Acute coronary syndrome (ACS) is a critical cardiac event that
leads to sudden cardiac death. Pathological studies suggest that
ACS is caused by thrombotic coronary occlusion after the rupture
of vulnerable plaques [6,7]. One of the morphological traits
typically associated with vulnerable plaques is a thin ﬁbrous cap,
sized around <65 mm that is heavily inﬁltrated with macrophages
and inﬂammatory cells [8]. Vascular inﬂammation is considered to
play a key role in plaque vulnerability, and previous studies have
found that serum inﬂammatory markers, such as high sensitive-C
reactive protein (hs-CRP), are associated with the presence of
vulnerable plaques [9–11]. In addition, consumption of n-3 PUFAs
such as EPA has been reported to decrease plasma concentrations
of inﬂammatory biomarkers [12].
Optical coherence tomography (OCT) is a safe and effective
modality for visualizing various features of vulnerable plaques, reserved.
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ratio is reported to be associated with higher plaque vulnerability
assessed by OCT in patients with stable angina pectoris [14]. How-
ever, the relationship between EPA/AA ratio and plaque vulnera-
bility assessed by OCT in ACS patients has not been examined in
detail. The purpose of this study was to compare the serum EPA/AA
ratio between patients with and without TCFA as determined by
OCT, and to investigate the relationship between the EPA/AA ratio
and plaque vulnerability in patients with ACS.
Materials and methods
Study population
We identiﬁed 350 consecutive ACS patients who had a de novo
culprit lesion and underwent percutaneous coronary intervention
(PCI) between March 2008 and November 2011 at Saitama Medical
Center, Jichi Medical University. Patients who did not undergo OCT
(n = 282) were excluded, and 68 patients were selected as the
study samples. They underwent OCT, which was performed by a
single investigator (H. F.). Prior to performing OCT, the investigator
applied the following exclusion criteria: signiﬁcant left main
coronary artery disease, ostial lesions, cardiogenic shock, the use of
intra-aortic balloon pumping, chronic renal failure on hemodialy-
sis, heavily calciﬁed lesions, and failure to attain thrombolysis in
myocardial infarction (TIMI) grade 3 coronary ﬂow. We excluded
2 patients who had a history of treatment with oral puriﬁed EPA
and 4 patients with missing serum PUFA data. In addition,
3 patients were excluded because we could not assess their plaque
characteristics because of low-quality OCT images. Thus, data from
59 patients with ACS [ST-elevation myocardial infarction
(STEMI) = 28; non-STEMI = 8; and unstable angina pectoris = 23]
were used in the ﬁnal analysis (Fig. 1). ACS was deﬁned as acute
myocardial infarction and unstable angina pectoris. Acute myo-
cardial infarction was deﬁned as elevated cardiac markers (i.e.
creatine kinase-myocardial band or troponin T) along with chest
pain persisting for >30 min, hospital arrival within 12 h of chest
pain onset, new ST-T wave changes, or a new left bundle branch
block on a 12-lead electrocardiogram [15]. Unstable anginaACS patie nts who had a de novo culprit  le sio 
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n = 35 
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Fig. 1. Flowchart.
ACS, acute coronary syndrome; EPA, eicosapentaenoic acid; OCT, optical coherence tomo
TCFA, thin-cap ﬁbroatheroma.pectoris was deﬁned as the presence of angina at rest, occurring
during the preceding 48 h with signiﬁcant transient ischemic ST-
segment and/or T-wave changes and without a signiﬁcant increase
in serum creatine kinase level (Braunwald class III-B). Hyperten-
sive patients were deﬁned as those with a systemic arterial
pressure >140/90 mmHg or those already taking anti-hyperten-
sive drugs. Diabetes patients were deﬁned as those with fasting
plasma glucose level >126 mg/dL, casual plasma glucose level
200 mg/dL, or those already taking oral drugs for diabetes
mellitus or receiving insulin therapy. Patients with dyslipidemia
were deﬁned as those with levels of low-density lipoprotein
cholesterol >140 mg/dL, high-density lipoprotein cholesterol
<40 mg/dL, triglycerides >150 mg/dL, or those already taking
lipid-lowering drugs. Patient data were obtained from medical
records and analyzed retrospectively. The study protocol was
approved by the Ethics Committee of Saitama Medical Center, Jichi
Medical University.
Coronary angiography and intervention
Cardiac catheterization was performed via the femoral or radial
artery using 6- or 7-Fr sheaths and catheters after a loading dose of
oral aspirin (162 mg) and clopidogrel (300 mg) was administered.
The culprit lesion was identiﬁed on the basis of coronary
angiography, electrocardiography, and echocardiography ﬁndings.
Intravenous heparin (100 U/kg) was administered before the
coronary intervention, and an additional dose was repeated as a
routine protocol in our hospital.
OCT image acquisition and analysis
OCT was performed at the culprit lesion. If the patient did not
have TIMI grade 3 coronary ﬂow, aspiration thrombectomy was
performed before OCT image acquisition. We advanced a 0.016-
inch OCT catheter (ImageWire; LightLab Imaging, Westford, MA,
USA) to the distal end of the culprit lesion through a 4-Fr occlusion
balloon catheter. In order to remove blood from the ﬁeld of view,
the coronary artery was occluded within 1 min using a balloon
catheter at the proximal site of the artery, and Ringer’s solutionn and  underw ent PCI bet wee n March 1, 
ber 30,  20 11
0 
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imaged with an automatic pullback device moving at 1 mm/s.
OCT images were analyzed with proprietary ofﬂine software
provided by LightLab Imaging. Two independent experienced
observers blinded to the patients’ clinical backgrounds analyzed
the OCT images. In case of disagreement, a consensus reading was
obtained. Signal-poor lesions with unclear borders indicated a lipid
core, and homogenous signal-rich lesions overlying a lipid core
indicated a ﬁbrous cap. The ﬁbrous cap thickness was measured
3 times at the thinnest part, and the average thickness was used for
the analysis. The lipid content of a plaque was semi-quantiﬁed as
the number of involved quadrants on a cross-sectional OCT image.
When a lipid core was present in 2 or more quadrants, it was
considered a lipid-rich plaque (Fig. 2A). TCFA was deﬁned as a
lipid-rich plaque with a ﬁbrous cap thickness <65 mm (Fig. 2B).
Ruptured plaque was deﬁned as the presence of ﬁbrous cap
discontinuity and cavity formation in the plaque (Fig. 2C).
Intracoronary thrombus was deﬁned as a mass protruding into
the vessel lumen from the surface of the vessel wall (Fig. 2D) [16].
Blood samples
Blood samples were acquired in a fasting state to measure levels
of the PUFAs, including EPA, AA, docosahexaenoic acid (DHA), and
dihomo-gamma-linolenic acid on the ﬁrst weekday morning after
admission. The measurements were outsourced to SRL (Tokyo,
Japan). In brief, plasma lipids were extracted by the Folch
procedure, and then fatty acids (tricosanoic acid, C23:0, as the
internal standard) were methylated with boron triﬂuoride andFig. 2. OCT images of a typical lipid-rich plaque, TCFA, ruptured plaque, and intracoronar
Ruptured plaque (arrow). (D) Intracoronary thrombus (arrows). OCT, optical coherencemethanol. The methylated fatty acids were subsequently analyzed
using a capillary gas chromatograph (GC-2010; Shimazu, Kyoto,
Japan).
Statistical analysis
Statistical analysis was performed using SPSS version 19 (SPSS,
Inc., Chicago, IL, USA). Continuous variables were expressed as the
mean  standard deviation for normally distributed variables or as
the median (interquartile range) for nonparametric variables. The
normality of the data was assessed using the Shapiro–Wilk test.
Comparisons for normally distributed variables were performed with
independent sample unpaired t-test. Non-parametric variables were
analyzed with the Mann–Whitney U-test. Categorical data were
presented as numbers (%) and analyzed using the x2 test. The
relationship between EPA/AA and ﬁbrous cap thickness was
evaluated using Spearman’s rank correlation coefﬁcient. Multivariate
logistic regression analysis was used to identify signiﬁcant predictors
of TCFA presence. Factors showing p < 0.2 in the independent sample
unpaired t-test, Mann–Whitney U-test, or x2 test were entered into
multivariate models. A receiver operating characteristic (ROC) curve
was constructed to identify optimal EPA/AA cut-off points and true-
positive (sensitivity) and false-positive rates (1-speciﬁcity) of EPA/
AA for predicting TCFA. The reproducibility of ﬁbrous cap thickness
measurements was evaluated according to intra-observer and inter-
observer differences, and inter-observer variability was also
evaluated by linear regression. Inter-observer agreement for TCFA
identiﬁcation was evaluated by the Cohen k test of concordance. A
p-value <0.05 was considered statistically signiﬁcant.y thrombus. (A) Lipid-rich plaque. (B) TCFA. The ﬁbrous cap (arrows) was 50 mm. (C)
 tomography; TCFA, thin-cap ﬁbroatheroma.
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Baseline characteristics of the included patients are shown in
Table 1. Overall, TCFA was observed in 54% of patients (32/59);
TCFA was also observed in 79% of patients with STEMI (22/28) and
32% of patients with non-STEMI or unstable angina pectoris (10/
31). Only age, clinical presentation, EPA, DHA, and the EPA/AA ratio
differed signiﬁcantly between the patients with and without TCFA.
Fig. 3 shows a comparison of the EPA/AA ratio and hs-CRP levels
between the patients with and without lipid-rich plaque, TCFA,
ruptured plaque, or thrombus. The EPA/AA ratio was signiﬁcantly
lower in patients with lipid-rich plaque, TCFA, and ruptured plaque
than in patients without these parameters. Serum hs-CRP levels
were signiﬁcantly higher only in patients with ruptured plaques
than in patients without ruptured plaques. The multivariate
logistic regression analysis revealed that the serum EPA/AA ratio
was signiﬁcantly associated with TCFA (Table 2). Fig. 4 shows the
relationship between the EPA/AA ratio and ﬁbrous cap thickness
and the ROC curve for the presence of TCFA using the EPA/AA ratio.
The EPA/AA ratio had a signiﬁcant positive correlation with ﬁbrous
cap thickness. ROC analysis showed that the EPA/AA ratio could
predict the presence of TCFA with 81.3% sensitivity and 74.1%
speciﬁcity at a cut-off value of 0.46 (area under the curve: 0.79).
Intra- and inter-observer differences for the measurements of
ﬁbrous cap thickness were low (12.5  7.1 and 8.1  8.1 mm,Table 1
Baseline characteristics.
Variable Patients without TCFA (n = 27) 
Age (years) 67 (64.0–72.0) 
Men 17 (63.0) 
BMI (kg/m2) 24 (22.4–26.1) 
Clinical presentation 
STEMI 6 (22.2) 
NSTEMI 6 (22.2) 
UAP 15 (55.6) 
Hypertension 12 (44.4) 
Dyslipidemia 23 (85.2) 
Diabetes mellitus 9 (33.3) 
Active smoker 10 (37.0) 
HbA1c (%) 5.5 (5.2–6.1) 
Hs-CRP (mg/dl) 0.16 (0.05–0.29) 
BUN (mg/dl) 14 (11–16) 
Creatinine (mg/dl) 0.74 (0.61–0.82) 
Uric acid (mg/dl) 5.3  1.1 
Total-C (mg/dl) 204.8  61.0 
HDL-C (mg/dl) 45 (36–53) 
LDL-C (mg/dl) 128.3  40.6 
TG (mg/dl) 96.0 (74.0–205.0) 
BS (mg/dl) 115.0 (97.0–151.0) 
g LA (mg/ml) 31.2  14.2 
AA (mg/ml) 128.6  55.4 
EPA (mg/ml) 67.5 (44.6–95.7) 
DHA (mg/ml) 136.6  62.0 
EPA/AA ratio 0.54 (0.42–0.70) 
Culprit vessel 
RCA 6 (22.2) 
LAD 18 (66.7) 
LCX 3 (11.1) 
Multivessel disease 7 (25.9) 
Medication
Aspirin 2 (7.4) 
b Blockers 3 (11.1) 
ACEIs or ARBs 5 (18.5) 
Statins 1 (3.7) 
Values are mean  SD or number of patients (%) or median (interquartile range). AA, a
receptor blocker; BMI, body mass index; BS, blood sugar; BUN, blood urea nitrogen; DHA,
high-density lipoprotein cholesterol; Hs-CRP, high sensitive-C reactive protein; LAD, left a
cholesterol; NSTEMI, non-ST-elevation myocardial infarction; RCA, right coronary arte
triglyceride; Total-C, total cholesterol; UAP, unstable angina pectoris; g LA, g linolenic arespectively). The correlation coefﬁcients were high for measure-
ments by 2 different observers (r = 0.94). Inter-observer variability
yielded acceptable concordance for the presence of TCFA (k = 0.90).
We also identiﬁed 40 patients with TCFA and/or ruptured
plaque and 19 patients without both TCFA and ruptured plaque.
The EPA/AA ratio was signiﬁcantly lower in patients with TCFA
and/or ruptured plaque than in those without both [0.36,
interquartile range (0.23–0.46) vs. 0.59, interquartile range
(0.49–0.80); p < 0.001]. According to multivariate logistic regres-
sion analysis, the EPA/AA ratio was also an independent predictor
of TCFA and/or ruptured plaque (odds ratio, 0.02; 95% conﬁdence
interval, 0.001–0.47; p = 0.01).
Discussion
The present study showed that the EPA/AA ratio was
signiﬁcantly lower in patients with TCFA than in those without
TCFA. Furthermore, the EPA/AA ratio was positively correlated
with ﬁbrous cap thickness and could predict the presence of TCFA
in patients with ACS.
Vascular inﬂammation plays an important role in atheroscle-
rosis, and the interaction between the inﬂammatory cells and
vascular endothelium is important. Endothelial cells up-regulate
the expression of adhesion molecules, which enables the recruit-
ment of monocytes into the intima. These monocytes differentiatePatients with TCFA (n = 32) p
62 (51.8–70.3) 0.02
27 (84.4) 0.06
24.4 (23.0–27.1) 0.55
<0.001
22 (68.8)
2 (6.3)
8 (25.0)
12 (37.5) 0.59
23 (71.9) 0.22
7 (21.9) 0.32
16 (50.0) 0.32
5.4 (5.1–5.8) 0.21
0.16 (0.09–0.26) 0.84
14 (11–16) 0.87
0.69 (0.60–0.90) 0.87
5.6  1.2 0.38
203.5  45.2 0.93
45 (38–55) 0.89
127.0  35.7 0.90
127.5 (74.8–171.3) 0.98
132.5 (111.5–151.3) 0.11
33.7  14.5 0.52
121.3  36.7 0.55
37.2 (24.2–53.3) <0.001
88.2  31.4 0.001
0.35 (0.21–0.44) <0.001
0.84
9 (28.1)
19 (59.4)
4 (12.5)
8 (25.0) 0.94
1 (3.1) 0.46
4 (12.5) 0.87
5 (15.6) 0.77
3 (9.4) 0.39
rachidonic acid; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
 docosahexaenoic acid; EPA, eicosapentaenoic acid; HbA1c, hemoglobin A1c; HDL-C,
nterior descending artery; LCX, left circumﬂex artery; LDL-C, low-density lipoprotein
ry; STEMI, ST-elevation myocardial infarction; TCFA, thin-cap ﬁbroatheroma; TG,
cid.
00.2
0.4
0.6
0.8
1
1.2
Lipid ri ch
plaque  (-)
n = 19
Lipid ri ch
plaque  (+)
n = 40
EP
A/
AA
0
0.2
0.4
0.6
0.8
1
1.2
TCFA (- )
n = 27
TCFA (+ )
n = 32
EP
A/
AA
p < 0.00 1 p < 0.00 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Thrombus (-)
n = 17
Thrombus (+)
n = 42
EP
A/
AA
0
0.2
0.4
0.6
0.8
1
1.2
Rupt ured
plaqu e (-)
n = 25
Rupt ured
plaque  (+)
n = 34
EP
A/
AA
p < 0.0 5 ns
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
TCFA (- )
n = 27
TCFA (+ )
n = 32
Hs
-C
RP
 (m
g/
dl
)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Lipid ri ch
plaque  (-)
n = 19
Lipid ri ch
plaque  (+)
n = 40
Hs
-C
RP
 (m
g/
dl
)
ns ns
0
0.2
0.4
0.6
0.8
1
1.2
Rupt ured
plaque  (-)
n = 25
Rupt ured
plaque  (+)
n = 34
Hs
-C
RP
 (m
g/
dl
)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Thrombus (-)
n = 17
Thrombus (+)
n = 42
Hs
-C
RP
 (m
g/
dl
)
p < 0.0 5 ns
A
B
Fig. 3. Comparison of the EPA/AA ratio (A) and hs-CRP levels (B) between the patients with and without lipid-rich plaque, TCFA, ruptured plaque, or thrombus. The median and
10th, 25th, 75th, and 90th percentiles are shown. AA, arachidonic acid; EPA, eicosapentaenoic acid; hs-CRP, high sensitive-C reactive protein; ns, not signiﬁcant; TCFA, thin-
cap ﬁbroatheroma.
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contribute to the formation of necrotic core and thinning of the
ﬁbrous cap, which characterize the TCFA [17,18]. In the present
study, we found a relationship between a low EPA/AA ratio and the
TCFA assessed by OCT. Although AA acts as a pro-inﬂammatoryTable 2
Multivariate logistic regression analyses: predictors of TCFA.
Univariate 
OR (95% CI) 
Age 0.94 (0.89–0.99) 
Men 3.18 (0.93–10.9) 
Clinical presentation 
STEMI 6.88 (1.98–23.9) 
NSTEMI 0.63 (0.10–3.84) 
BS 1.004 (0.99–1.01) 
DHA 0.97 (0.96–0.99) 
EPA/AA ratio 0.02 (0.001–0.32) 
AA, arachidonic acid; BS, blood sugar; CI, conﬁdence interval; DHA, docosahexaenoic a
OR, odds ratio; STEMI, ST-elevation myocardial infarction.agent, EPA acts as an anti-inﬂammatory agent to decrease the
production of pro-inﬂammatory eicosanoid mediators from AA,
decrease adhesion molecule expression and inhibit monocyte
adhesion to endothelial cells, and increase adiponectin secretion
and monocyte interleukin-10 expression [18–21]. In addition,Multivariate
p OR (95% CI) p
0.04 0.95 (0.88–1.03) 0.18
0.07 1.55 (0.27–8.94) 0.62
0.003 0.03
0.002 7.64 (1.53–38.0) 0.01
0.61 0.67 (0.07–6.89) 0.73
0.40 1.002 (0.99–1.02) 0.86
0.002 0.98 (0.96–1.002) 0.08
0.006 0.09 (0.007–0.99) 0.049
cid; EPA, eicosapentaenoic acid; NSTEMI, non-ST-elevation myocardial infarction;
Fig. 4. Relationship between ﬁbrous cap thickness and EPA/AA ratio (A) and ROC curve for the presence of TCFA using the EPA/AA ratio (B). AA, arachidonic acid; AUC, area
under the curve; EPA, eicosapentaenoic acid; ROC, receiver operating characteristic; TCFA, thin-cap ﬁbroatheroma.
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levels of pentraxin 3, an inﬂammatory marker that was associated
with TCFA [22,23]. Although the precise mechanism is unknown,
these activations of EPA and AA may contribute to the relationship
between a low EPA/AA ratio and TCFA.
Previous studies investigated the association between serum
DHA levels and plaques. One study found a signiﬁcant decrease in
DHA levels with progression of coronary plaque volume [24]. Ad-
ditionally, Cawood et al. examined n-3 PUFA incorporation into
atherosclerotic plaques in patients who consumed low doses of
EPA and DHA (0.81 g of EPA/day and 0.675 g of DHA/day). They
found that the proportion of DHA in carotid plaque phospholipids
was not signiﬁcantly higher in the intervention group than in the
control group, although the proportion of EPA was signiﬁcantly
higher in the intervention group. They also showed that a higher
content of EPA in carotid plaques was associated with less
inﬂammation and increased plaque stability [25]. In the present
study, we showed the association between low serum DHA levels
and the presence of TCFA. However, DHA level was not an
independent predictor of TCFA according to the multivariate
analysis; thus, we consider that TCFA may be affected more by EPA/
AA ratio than by DHA level.
Our study found a signiﬁcant relationship between hs-CRP and
plaque rupture, and this ﬁnding is consistent with those of
previous intravascular ultrasound or OCT studies [23,26,27]. Con-
trary to our expectations, we did not ﬁnd a signiﬁcant association
between hs-CRP and the presence of TCFA. In accordance with a
previous report on this subject, the serum levels of hs-CRP were
signiﬁcantly higher in patients with TCFA than in those without
TCFA [27]. However, Koga et al. reported no signiﬁcant differences
in serum hs-CRP levels between patients with TCFA and those
without TCFA [23]. The most likely explanation for these
discrepancies is that TCFA may not be the sole factor underlying
systemic inﬂammation, and plaque rupture could play a signiﬁcant
role in inﬂammation.
Study limitations
This study had certain limitations. First, it was a single-center
study, and the population was relatively small. Second, we
evaluated only patients who underwent OCT performed by a
single cardiologist. Therefore, the possibility of selection biascannot be eliminated. Third, some OCT images of poor quality, due
to incomplete blood displacement or thrombi that could shadow or
obscure underlying structures, were excluded from the analysis; this
may also have contributed to selection bias. Fourth, aspiration
thrombectomy was performed for reperfusion in patients with TIMI
ﬂow grade 2. The thrombectomy catheter may have modiﬁed
lesion morphologies, but imaging before treatment would not have
been ethically appropriate. Fifth, ruptured plaque with a ﬁbrous cap
thickness 65 mm may have been the TCFA before the rupture, and it
may not be appropriate to deﬁne these plaques as non-TCFA.
Therefore, we analyzed the association between EPA/AA ratio and
TCFA and/or ruptured plaque, and we found that EPA/AA ratio could
predict the presence of TCFA and/or ruptured plaque. Sixth, the
serum hs-CRP levels were measured in the acute phase and may
have indicated not only the plaque inﬂammation but also the
myocardial damage due to ACS. Seventh, information on diet and
nutrient intake was not available. This may have affected serum
PUFA levels or plaque characteristics. Finally, this was a cross-
sectional study, and we did not assess whether the EPA/AA ratio
could predict future clinical outcomes. Further large-scale longitu-
dinal prospective studies are needed to address these issues.
Conclusions
A low serum EPA/AA ratio was found to be associated with the
presence of TCFA assessed by OCT in ACS patients. These ﬁndings
suggest that a low serum EPA/AA ratio can serve as a biomarker of
plaque vulnerability.
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